Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COLOVAGE vs ORPHENGESIC FORTE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
COLOVAGE is a bowel cleansing preparation containing polyethylene glycol 3350 and electrolytes. It acts as an osmotic laxative, causing fluid retention in the colon to stimulate bowel evacuation.
Opioid agonist; primarily mu-opioid receptor agonism, with additional kappa and delta receptor activity, leading to altered pain perception and analgesic response.
Colonoscopy preparation,Bowel cleansing prior to colorectal surgery
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
4 liters of PEG-3350 electrolyte solution orally as a single dose for colon cleansing prior to colonoscopy; alternatively, 2 liters with ascorbic acid regimen.
1-2 tablets (325-650 mg acetaminophen/30-60 mg codeine) orally every 4-6 hours as needed; maximum 8 tablets per day.
Not applicable (non-absorbed, gut lavage); systemic absorption minimal
2-4 hours; prolonged to 10-20 hours in hepatic impairment.
Polyethylene glycol 3350 is not absorbed systemically; no hepatic metabolism.
Primarily hepatic via CYP3A4 and CYP2D6; major metabolites: morphine-3-glucuronide (M3G), morphine-6-glucuronide (M6G).
Primarily fecal as unabsorbed drug; negligible renal excretion (<5%)
Renal: 87% (55% unchanged, 32% as glucuronide conjugate); Biliary/Fecal: <5% as metabolites.
Not applicable (minimal systemic absorption)
90-95% bound to albumin and alpha-1-acid glycoprotein.
Not applicable (limited to gastrointestinal tract)
2.5-3.0 L/kg; extensive tissue distribution, notably to brain and skeletal muscle.
Oral: <0.3% systemically absorbed
Oral: 85-90%; Rectal: 70-80% (first-pass metabolism).
Contraindicated in GFR <30 m L/min/1.73 m²; for GFR 30-60 m L/min/1.73 m², use with caution due to risk of electrolyte imbalance, no dose adjustment recommended.
GFR 30-50 m L/min: administer every 6 hours; GFR 10-29 m L/min: administer every 8 hours; GFR <10 m L/min: not recommended.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to potential fluid and electrolyte disturbances.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval; Child-Pugh C: contraindicated.
Not indicated for patients under 18 years of age; no established weight-based dosing.
Weight-based dosing: Acetaminophen 10-15 mg/kg/dose and codeine 0.5-1 mg/kg/dose orally every 4-6 hours; maximum acetaminophen 75 mg/kg/day. Not for children <12 years due to codeine safety concerns.
No specific dose adjustment, but monitor for electrolyte disturbances, dehydration, and aspiration risk; consider split-dose regimen or lower volume if tolerated.
Start at low end of dosing (e.g., 1 tablet every 6 hours) due to increased sensitivity and risk of respiratory depression. Maximum 4 tablets per day.
Risk of fluid and electrolyte abnormalities (e.g., hyponatremia, seizures) in patients with impaired renal function, dehydration, or those taking medications affecting electrolytes.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants.
Monitor for fluid and electrolyte disturbances, especially in elderly, debilitated, or renal impaired patients. Use with caution in patients with gastrointestinal obstruction, ileus, or severe colitis.
Respiratory depression; hypotension; seizure risk; serotonin syndrome; adrenal insufficiency; severe hypotension; gastrointestinal obstruction; impaired mental/physical abilities.
Gastrointestinal obstruction, ileus, gastric retention, bowel perforation, toxic colitis or megacolon, hypersensitivity to any component.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected gastrointestinal obstruction including paralytic ileus; hypersensitivity to morphine or any component.
Only clear liquids (e.g., water, clear broth, black coffee/tea, clear juices) are allowed during bowel preparation. Avoid all solid foods, dairy products, red or purple liquids, and alcohol. Do not consume any food containing pulp or seeds.
Avoid grapefruit juice as it may increase caffeine levels. Limit caffeine intake from coffee, tea, or soda to prevent overstimulation. High-fat meals may delay absorption of orphenadrine.
Colovage (polyethylene glycol 3350) is not absorbed systemically; no teratogenic risk anticipated in any trimester. No fetal risks reported with oral use.
Orphengesic Forte (orphenadrine citrate, aspirin, and caffeine) carries significant teratogenic risk due to aspirin. First trimester: Aspirin is associated with neural tube defects and cardiovascular malformations (odds ratio ~2-3). Second trimester: Possible increased risk of gastroschisis. Third trimester: High risk of premature closure of ductus arteriosus, oligohydramnios, and fetal intracranial hemorrhage. Orphenadrine: Limited human data; animal studies show no consistent teratogenicity. Caffeine: High doses (>300 mg/day) may increase miscarriage risk. Overall: Contraindicated in pregnancy, especially third trimester.
Due to lack of systemic absorption, excretion into breast milk is negligible. Colovage is considered compatible with breastfeeding. M/P ratio: not applicable.
Orphengesic Forte components are excreted into breast milk. Aspirin: M/P ratio ~0.01-0.1; risk of Reye syndrome in infant; avoid high doses. Orphenadrine: M/P ratio unknown; may cause anticholinergic effects (drowsiness, irritability). Caffeine: M/P ratio ~0.5-0.8; can cause infant irritability and sleep disturbances. Recommend avoiding due to potential adverse effects.
No dose adjustment necessary; pharmacokinetics unchanged as drug is not absorbed.
Aspirin: Increased clearance and volume of distribution in pregnancy; empirical dose adjustments not recommended due to teratogenicity; avoid entirely. Orphenadrine: No data on pharmacokinetic changes; dose adjustments not applicable as contraindicated. Caffeine: Pregnancy reduces caffeine clearance by 50% in third trimester; no adjustment applicable as contraindicated. Overall: No safe dose in pregnancy; contraindicated.
COLOVAGE (polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, ascorbic acid) is a high-volume colon cleansing preparation. Ensure adequate hydration before, during, and after use. Monitor for electrolyte disturbances in patients with renal impairment or those taking diuretics. Split-dose regimen improves tolerance and cleansing quality. Avoid use in patients with gastrointestinal obstruction, perforation, or toxic megacolon.
Orphengesic Forte combines orphenadrine (a centrally acting muscle relaxant) with acetaminophen and caffeine. Use with caution in elderly due to anticholinergic effects (confusion, urinary retention). Avoid in patients with myasthenia gravis, glaucoma, or GI obstruction. Caffeine may exacerbate anxiety or insomnia.
Follow the split-dose regimen exactly as prescribed to achieve optimal bowel cleansing.,Drink additional clear liquids as directed to prevent dehydration.,Do not eat any solid food while taking the preparation; only clear liquids are allowed.,Expect frequent, watery stools; stay near a restroom.,Contact your doctor if you experience severe abdominal pain, vomiting, or signs of dehydration.
Take with food or milk to reduce stomach upset.,Avoid alcohol as it increases sedation and liver toxicity risk.,Do not drive or operate machinery until you know how this drug affects you.,Contact your doctor if you experience rapid heartbeat, difficulty urinating, or vision changes.,Do not take other products containing acetaminophen (Tylenol) or caffeine to avoid overdose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COLOVAGE vs ORPHENGESIC FORTE, answered by our medical review team.
COLOVAGE is a Osmotic Laxative that works by COLOVAGE is a bowel cleansing preparation containing polyethylene glycol 3350 and electrolytes. It acts as an osmotic laxative, causing fluid retention in the colon to stimulate bowel evacuation.. ORPHENGESIC FORTE is a Muscle relaxant combination that works by Opioid agonist; primarily mu-opioid receptor agonism, with additional kappa and delta receptor activity, leading to altered pain perception and analgesic response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COLOVAGE and ORPHENGESIC FORTE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COLOVAGE is: 4 liters of PEG-3350 electrolyte solution orally as a single dose for colon cleansing prior to colonoscopy; alternatively, 2 liters with ascorbic acid regimen.. The standard adult dose of ORPHENGESIC FORTE is: 1-2 tablets (325-650 mg acetaminophen/30-60 mg codeine) orally every 4-6 hours as needed; maximum 8 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COLOVAGE and ORPHENGESIC FORTE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COLOVAGE is classified as Category C. Colovage (polyethylene glycol 3350) is not absorbed systemically; no teratogenic risk anticipated in any trimester. No fetal risks reported with oral use.. ORPHENGESIC FORTE is classified as Category C. Orphengesic Forte (orphenadrine citrate, aspirin, and caffeine) carries significant teratogenic risk due to aspirin. First trimester: Aspirin is associated with neural tube defects. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.